RxDoctor Payments Data

Michael Gordon, MD

Ophthalmology · San Diego, CANPI 1851489355

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $85,000 of the $103,482 with a category attached, or 82.1%. Alcon accounts for 61.2% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2024 at $38,647 and has fallen 94.3% since, to $2,189 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$103,482in general payments, 2019–2025

Across 208 payments — averaging $497.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$63K
  • Alcon Research LLC$37K
  • Glaukos Corporation$1K
  • Avedro Inc.$1K
  • Bausch & Lomb Americas Inc.$247
  • Johnson & Johnson$227
  • plus $1K from 15 others
$476,880in research payments, 2019–2025

Across 558 payments — averaging $854.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alcon Research LLC$412K
  • Novartis$65K

What the payments were for

  • Consulting fees$85,00082%
  • Speaking & faculty fees$7001%
  • Travel & lodging$10,39810%
  • Food & beverage$7,3847%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$103,482 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California →

Medicare billing

Part B allowed, 2024
$173,207
Medicare patients
214
Services billed
928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate45$1,114
MoxifloxacinMoxifloxacin Hcl44$939
Ketorolac Tromethamine31$321
Atropine Sulfate17$256

Paid to pharmacies, not to this prescriber.

Other ophthalmology in San Diego

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →